Robert Hodge joined COUR in 2023 as VP of Technical Development where he oversees late-stage process and product development, analytics, and preparations for commercialization.
Prior to joining COUR, Robert was a Principal Consultant at TheraPartners since 2021. Before this, Robert served as VP, Technical Development for AveXis, Inc. and then Novartis Gene Therapies after AveXis was acquired by Novartis in 2018. From 2012 to 2016, Robert was Director Manufacturing Science and Technology for Hospira and then Pfizer after Pfizer acquired Hospira in 2015. Before this, he was Sr. Director Manufacturing at Kythera Biopharmaceuticals Inc from 2006 to 2012. From 1990 to 2005, Robert held various positions in manufacturing and development at Amgen Inc.
Robert received a Bachelor of Science in Chemical Engineering from UC Santa Barbara.